The global DNA methylation market is expected to garner a market value of USD 1437.5 Million in 2023 and is expected to accumulate a market value of USD 5815.49 Million by registering a CAGR of 15% in the forecast period 2023 to 2033.
Growth of the DNA methylation market can be attributed to increasing cases of cancer globally remains the primary driver of its anticipated growth. The market for DNA methylation registered a CAGR of 11% in the historical period 2016 to 2021.
Furthermore, the declining cost of treatment with streamlining of product approvals also remains a steady driver of growth. Significant government support for research and development activities with direct funding continues to open new opportunities for growth.
| Report Attribute | Details |
|---|---|
| Expected Market Value (2023) | USD 1437.5 Million |
| Anticipated Forecast Value (2033) | USD 5815.49 Million |
| Projected Growth Rate (2023 to 2033) | 15% CAGR |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
According to market research and competitive intelligence provider Future Market Insights- the market for DNA methylation reflected a value of 9% during the historical period, 2017 to 2021.
DNA methylation remains a promising technique to advance research in core areas of chronic disease treatment. In September 2022, researchers from the University of California published a journal in Nature Communications stating the potential application of cell-free DNA methylation as a promising biomarker for cancer detection at an early stage.
Thus, the market for DNA methylation is expected to register a CAGR of 16.30% in the forecast period 2023 to 2033.
Accessibility to test kits increasing the use of DNA methylation
The COVID-19 outbreak impacted the market negatively due to movement restrictions, which hindered research and testing at research centers and laboratories. However, the post-pandemic, reopening of research institutions resulted in increased usage of DNA methylation. Moreover, the accessibility of a broad range of test kits has further created significant opportunities for market players.
The DNA methylation analysis technique helps scientists gain valuable insights into gene regulation and potential biomarker identification. Abnormal DNA methylation has been associated with several disease processes, such as obesity, cancer, and others.
It also promises potential application in agronomic research to study responses to temperature extremes, drought, and other environmental changes. In June 2022, a research article published in MDPI stated that DNA methylation is mostly studied in epigenetic marks in plants and others. It is considered a sustainable source of variation contributing to crop production and health.
Advanced technology and next-generation technology favoring the growth of the DNA methylation market
Furthermore, various high-throughput technologies such as microarrays and next-generation sequencing (NGS) have facilitated studies related to genome-wide methylation profiling. These technologies offer ways to understand DNA methylation significance, providing insights into the functional effects of variation.
For instance, in February 2021, Twist Bioscience launched the NGS Methylation Detection System, which is to be used for the analysis of liquid biopsy cancer and epigenetic studies. This would further provide insight into disease pathology.
Principal Consultant
Lack of expertise and unskilled professionals creating obstacles to market growth
A lack of expertise to perform DNA methylation experiments could restrict the growth. DNA methylation holds significant potential in various biotechnology applications, while the relatively low number of skilled professionals remains an obstacle to growth. All these factors may restrict the growth of the DNA methylation market in the forecast period 2023 to 2033.
Investments in research accelerating DNA methylation market growth
North America is expected to account for the largest market share in 2023. This can be attributed to the large network of manufacturing and Research and Development facilities, and the increase in product launches and approvals. Moreover, the growing demand for protein expression systems has also contributed significantly to regional growth.
In May 2022, Twist Bioscience introduced a human methylome panel to allow methylation fractions to be detected in a wide range of applications. This supports the identification of epigenetic targets and the discovery of differentially methylated areas for human development and cancer metastasis research.
North America’s contribution through research and development is creating lucrative opportunities for DNA methylation. Thus, North America is expected to possess a 40% market share in the DNA methylation market in 2023.
Global players penetrating the Asia Pacific market region for wider reach
Asia Pacific is estimated to be the fastest-growing segment over the forecast period due to growing support from the government with several initiatives. Furthermore, the growing focus of global players on emerging markets of Asia Pacific also remains a promising driver of growth.
In September 2020, AnchorDxentered announced the development of a liquid biopsy diagnostic model for breast cancer detection at an early stage. This diagnostic model is focused on circulating cell-free DNA-based methylation patterns. Similarly, in August 2022, Oncgnostics GmbH received authorization from the Chinese government to market its GynTect test to doctors and patients.
This is the first methylation test to be authorized in China for the triage of cervical cancer cases. Thus, Asia Pacific is expected to possess a 38% market share in the DNA methylation market in 2023.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Cost-effective and accurate results favoring the use of sequencing for DNA methylation
The sequencing segment captured the highest market share in 2021 due to the rapid advancement in technologies that offer cost-effective, accurate, and quick results. Bisulfite genomic sequencing is considered a gold-standard technology. Researchers have employed whole-genome bisulfite sequencing to understand the epigenetic landscape of immune-related disorders caused by tobacco use.
Growth of this technology in research studies to understand the adverse effects of smoking and how it relates to diseases promises further growth opportunities in the segment. Thus, sequencing is expected to possess a 35% market share in the DNA methylation market in 2023.
Demand for analyzing DNA making PCR essential for screening in DNA methylation
PCR is anticipated to witness significant growth in the coming years owing to an increase in its use in diagnostics and DNA sequencing procedures. During Covid-19, the demand for PCR technology significantly increased in relevance as a diagnostic procedure. PCR-based methods are primarily used to analyze DNA methylation on a gene-by-gene basis.
In May 2022, Pentabase A/S announced the launch of a qPCR-based assay, EpiDirect, for detecting DNA methylation without pre-treatment. This product aims to create a cancer screening technique that can detect cancers in a cell-free DNA environment.
Wide application in end-user industries making consumables a viable option
The consumables segment is expected to dominate the DNA methylation market in 2023, as it is majorly used in the DNA sequencing procedures and diagnosis process.
Growing demand for quick turnaround times and high throughput results are also strong contributors to the growth. A wide range of consumables is used in the research industry, which includes tubes, vials, microarray panels, dispensers, and pipette tips.
High volume requirements of these consumables continue to boost the overall demand in the market. In April 2022, PacBio announced of expansion of its product offering by adding new DNA methylation consumables. These are made directly available to all its customers using Sequel II and Sequel IIe systems. Thus, consumables are expected to possess a 35% market share in the DNA methylation market in 2023.
Protein-modifying enzymes experiencing lucrative growth for DNA methylation
The enzyme segment is anticipated to witness lucrative growth in the coming years due to the increasing demand for protein-modifying enzymes in the DNA methylation technique. These are widely used in agrigenomic research, genomic research, and genome-wide analysis.
The usage of enzymes in DNA methylation reactions during sequencing analysis, such as Illumina sequencing and pyrosequencing remains prominent. Moreover, the utilization of next-generation sequencing technology has bolstered the demand for enzymes in the biotechnology industry.
Demand for potential biomarkers increasing growth of clinical trials
The clinical research segment is expected to capture the highest market share in 2023, thanks to the increasing number of clinical trials for several diseases globally. Furthermore, increased Research and Development expenditure, and increasing demand for potential biomarkers promise more growth opportunities.
In July 2020, an article published in Springer stated that disease-linked methylation changes could be used as biomarkers at all clinical disease management stages. These various stages include predisposition and risk assessment screening through early diagnostics to the personalized patient care of chronic and relapse disease.
Therefore, disease-related discovery is a promising biomarker and a potential game-changer for precision medicine. Thus, clinical research is expected to possess a 40% market share of the DNA methylation market in 2023.
Accuracy of pathological diagnosis increasing dependency on diagnostic systems
The diagnostic segment is anticipated to witness the fastest growth in the coming years with a CAGR of 16%. DNA methylation profiling is an emerging tool that promises to increase the accuracy of pathological diagnosis.
In January 2022, an article published in PubMed stated that DNA methylation patterns in circulating tumor DNA (ctDNA) offer considerable promise for the categorization and detection of cancer with the least invasive approach. Methylation profiling can be widely used as a cancer diagnostic tool for all tumor types, despite its recent arrival on the scene
High throughput technologies boosting the use of DNA methylation in molecular biology and genomics
The pharmaceutical and biotechnology end-use segment is expected to capture the highest market share in 2023. The increased adoption of DNA methylation in the field of molecular biology and genomics & remains the primary driver of this growth.
Moreover, increasing usage of high throughput technologies such as NGS by key market players also continues to open new opportunities for growth.
In June 2020, Base Genomics announced of leveraging TET-assisted pyridine borane sequencing (TAPS) technology developed by the University of Oxford to find epigenetic signs of cancer in the blood. Thus, the pharmaceutical and biotechnology end-use segment is expected to possess a 42% market share for DNA methylation in 2023.
Research & development activities along with funding from the government contributing to research and academia segment
Research and Academia are anticipated to witness significant growth in the coming years owing to increased Research and Development in the epigenetics sector. This along with increasing government support in terms of funding remains a promising driver of growth.
In July 2022, according to a study published in Genome Biology, DNA methylation in bacteria controls reproduction, gene expression, and pathogenicity. The tissue-specific gene expression that regulates a cell's identity, such as if it’s a brain cell or a skin cell, is regulated by DNA methylation Quality research remains the backbone of growth in the market.
Key players in the DNA methylation market are Base Genomics, EpiQMAx, genknowme, Epify, and EpigenCare
Key players operating in the DNA methylation industry are taking several initiatives such as strategic collaborations, partnerships, and geographical expansion in emerging regions.
Some prominent players in the global DNA methylation market include New England Biolabs, Sysmex Corporation, Abcam plc., F. Hoffmann-La Roche Ltd., Diagenode Diagnostics S.A., Thermo-Fisher Scientific Inc., Agilent Technologies Inc., BioRad Laboratories Inc., Exact Sciences Corporation, QIAGEN N.V., Active Motif, Inc., Illumina Inc., EpiGentek Group Inc., Pacific Biosciences Inc., New England Biolabs Inc., Merck KGaA, Zymo Research Corporation, PerkinElmer Inc.
| Report Attribute | Details |
|---|---|
| Market Value in 2023 | USD 1437.5 Million |
| Market Value in 2033 | USD 5815.49 Million |
| Growth Rate | CAGR of 15% from 2023 to 2033 |
| Base Year for Estimation | 2022 |
| Historical Data | 2018 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | Revenue in USD Million and CAGR from 2023 to 2033 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis |
| Segments Covered | Technology, Product Type, Application, End Use, Region |
| Regions Covered | North America; Latin America; Western Europe; Eastern Europe; Asia Pacific Excluding Japan; Japan; Middle East and Africa |
| Key Countries Profiled | USA, Canada, Brazil, Argentina, Germany, United Kingdom, France, Spain, Italy, Nordics, BENELUX, Australia & New Zealand, China, India, ASEAN, GCC Countries, South Africa |
| Key Companies Profiled |
New England Biolabs; Sysmex Corporation; Abcam plc.; F. Hoffmann-La Roche Ltd.; Diagenode Diagnostics S.A.; Thermo-Fisher Scientific Inc.; Agilent Technologies Inc.; BioRad Laboratories Inc.; Exact Sciences Corporation; QIAGEN N.V.; Active Motif, Inc.; Illumina Inc.; EpiGentek Group Inc.; Pacific Biosciences Inc.; New England Biolabs Inc.; Merck KGaA; Zymo Research Corporation; PerkinElmer Inc. |
| Customization | Available Upon Request |
From 2017 to 2021, the DNA methylation market grew at a CAGR of 11%
The global DNA methylation market is expected to grow with a 15% CAGR from 2023 to 2033.
As of 2033, the DNA methylation market is expected to reach USD 5815.49 Million
Sequencing is expected to possess a 35% market share in the DNA methylation market in 2023.
The pharmaceutical and biotechnology end-use segment is expected to possess a 42% market share for DNA methylation in 2023.
Clinical research is expected to possess a 40% market share in the DNA methylation market in 2023.
North America is expected to possess a 40% market share in the DNA methylation market in 2023.
Asia Pacific is expected to possess a 38% market share in the DNA methylation market in 2023.
1. Executive Summary 2. Market Overview 3. Market Background 4. Global Market Analysis 2017 to 2021 and Forecast, 2022 to 2032 5. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Technology 5.1. Polymerase Chain Reaction (PCR) 5.2. Microarray 5.3. Sequencing 5.4. Others 6. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Product 6.1. Consumables 6.2. Kits & Reagents 6.3. Enzymes 6.4. Instruments & Software 7. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Application 7.1. Gene Therapy 7.2. Clinical Research 7.3. Diagnostics 7.4. Others 8. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By End-use 8.1. Hospital & Diagnostic Laboratories 8.2. Pharmaceutical & Biotechnology Companies 8.3. Research & Academia 9. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Region 9.1. North America 9.2. Latin America 9.3. Europe 9.4. South Asia 9.5. East Asia 9.6. Oceania 9.7. Middle East and Africa (MEA) 10. North America Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country 11. Latin America Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country 12. Europe Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country 13. South Asia Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country 14. East Asia Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country 15. Oceania Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country 16. MEA Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country 17. Key Countries Market Analysis 18. Market Structure Analysis 19. Competition Analysis 19.1. New England Biolabs 19.2. Sysmex Corporation 19.3. Abcam plc. 19.4. F. Hoffmann-La Roche Ltd. 19.5. Diagenode Diagnostics S.A. 19.6. Thermo-Fisher Scientific Inc. 19.7. Agilent Technologies Inc. 19.8. BioRad Laboratories Inc. 19.9. Exact Sciences Corporation 19.10. QIAGEN N.V. 19.11. Active Motif, Inc. 19.12. Illumina Inc. 19.13. EpiGentek Group Inc. 19.14. Pacific Biosciences Inc. 19.15. New England Biolabs Inc. 19.16. Merck KGaA 19.17. Zymo Research Corporation 19.18. PerkinElmer Inc. 20. Assumptions & Acronyms Used 21. Research Methodology
Explore Healthcare Insights
View Reports
DNA Methylation Market
